Philippe Picaut

Dr. Picaut has over 30 years of experience as a global biopharmaceutical executive and industry leader. Over his career at Rhône-Poulenc Rorer, Aventis, Pierre Fabre, Ipsen and AlgoTherapeutix. He has made important contributions to the research, development, and registration of drugs in the US/EU and Asia. Dr. Picaut has played leadership roles across multiple functions, including Preclinical Safety, Portfolio & Project Management, Business Development, Clinical Research, and as Neuroscience Therapeutic Area Head. Dr. Picaut’s experience spans all research and drug developmental stages in multiple therapeutic areas, such as Anti-infectives, Cardiovascular, Dermatology, Neurology, and Pain. Dr. Picaut has worked with various treatment modalities, including both small molecules and biologics. Most recently, Dr. Picaut served as Senior Vice President of R&D Neuroscience for Ipsen to drive the early-stage discovery to clinical activities for submission with Dysport worldwide and bringing new botulinum toxins having novel pharmacological profile from Discovery to clinical development stage. He is the co-author of more than 30 research and clinical publications in the field of botulinum toxins in Therapeutic and Esthetic.